Meeting
2016 ASCO Annual Meeting
Bevacizumab (bev) for metastatic colorectal cancer (mCRC): A global cost-effectiveness analysis.
Authors
Daniel A. Goldstein
Davidoff Centre, Rabin Medical Centre, Petach Tikvah, Israel
Daniel A. Goldstein , Qiushi Chen , Turgay Ayer , Kelvin K. Chan , Kiran Virik , Ariel Hammerman , Baruch Brenner , Christopher Flowers , Peter Hall
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Health Services Research and Quality of Care
Track
Health Services Research and Quality of Care
Sub Track
Value/Cost of Care
Citation
J Clin Oncol 34, 2016 (suppl; abstr 6518)
DOI
10.1200/JCO.2016.34.15_suppl.6518
Abstract #
6518
Poster Bd #
10
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Cost-effectiveness of cetuximab + FOLFIRI versus bevacizumab + FOLFIRI in the first-line treatment of RAS wild-type metastatic colorectal cancer in China.
First Author: Ilse Van Oostrum
Poster
2017 ASCO Annual Meeting
Cost-effectiveness of front-line trials in metastatic colorectal cancer: Integrating the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) with the costs of drugs..
First Author: Andrea Bonetti
Poster
2017 Gastrointestinal Cancers Symposium
Bevacizumab in addition to chemotherapy first-line for right-side metastatic colorectal cancer: A cost-effectiveness analysis.
First Author: Gong Chen
Poster
2017 Gastrointestinal Cancers Symposium
Cetuximab and bevacizumab in addition to chemotherapy first-line for left-side metastatic colorectal cancer: A cost-effectiveness analysis.
First Author: Yanqiao Zhang